top of page
Executive Spotlights

Weight-Loss Drug Startup Metsera Launches with $290M Funding

NY, NY, April 18, 2024 (Business Wire) -- Metsera, Inc., a pioneering player in the clinical-stage biopharmaceutical realm focusing on innovative treatments for obesity and metabolic ailments, has entered the scene. Established through a partnership between Population Health Partners and ARCH Venture Partners, and led by former executives of The Medicines Company, Metsera is set to revolutionize the sector. Prioritizing the development of a comprehensive array of oral and injectable therapies, including unique combinations of incretins and non-incretins, Metsera is dedicated to introducing cutting-edge solutions tailored to meet the dynamic needs of weight loss treatments.

Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma


Life Science Headlines
bottom of page